Rendering of interior to Cell and Gene Therapy Innovation Hub on Long Island

Governor Hochul Launches Next Phase of Long Island's Nation-Leading Cell and Gene Therapy Innovation Hub: New York Biogenesis Park

$430 Million Project Will Catalyze Research, Development, and Commercialization of Life-Saving Therapies

State's $150 Million Commitment Marks Largest State Investment in Cell and Gene Therapy Nationwide

Advances New York's Statewide Vision for Cell and Gene Therapy Leadership

View Renderings Here

Governor Kathy Hochul today unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

“With this groundbreaking hub, New York has the opportunity to stake its claim as the epicenter of cell and gene therapy innovation,” Governor Hochul said. “We're not just advancing medical science; we're creating a powerhouse that will drive our economy, generate thousands of high-skilled jobs, and bring hope to millions facing life-threatening diseases. This investment reaffirms our commitment to leading the future of healthcare and ensuring that the next medical breakthrough happens right here in New York.”

Empire State Development President, CEO, and Commissioner Hope Knight said, "The selection of a developer with proven expertise ensures the Long Island CGT Center would be a beacon of excellence from inception to operation. ESD’s landmark investment not only underscores New York's commitment to leadership in life sciences but also catalyzes a transformative shift in our biotechnology landscape. By creating high-quality jobs, attracting world-class talent, and fostering groundbreaking innovation, New York BioGenesis Park would cement New York's position at the forefront of cell and gene therapy globally, driving economic growth and scientific advancement in equal measure."

Read the full press release here.